Evaluating the GAAD score's effectiveness in detecting liver cancer in patients with chronic liver disease.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the impact of the GAAD score in conjunction with imaging techniques for patients with chronic liver disease who are eligible for hepatocellular carcinoma (HCC) surveillance. It will evaluate the diagnostic accuracy of the GAAD score for detecting HCC, including its sensitivity and specificity, and track changes in the GAAD score over time. A total of 1000 participants will be enrolled, and data will be collected over three years, with bi-annual imaging and GAAD score assessments performed as part of standard clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with cirrhosis
* Non-cirrhotic chronic hepatitis B patients meeting any of the following criteria: positive family history for HCC, intermediate-high aMAP and/or (m)PAGE-B score (if non-Caucasian)
* Non-cirrhotic chronic hepatitis C patients (with or without SVR) with a history of F3 fibrosis (based on histology or liver stiffness assessment)
* Non-cirrhotic NASH patients with a history of F3 fibrosis (based on histology or liver stiffness assessment)

Exclusion Criteria:

* Diagnosis with any other cancer other than non-melanoma skin cancer
* History of HCC
* Women who are pregnant or lactating
* Patient with glomerular filtration rate \<45 ml /min/1.73 m2
* Unwillingness or inability to undergo both CT and MRI imaging
* Life expectancy \<2 years
* Use of vitamin K antagonists

Where it's running

• Erasmus MC
  Rotterdam, Ca, Netherlands Recruiting

Study contacts

• Principal investigator: M. J. Sonneveld, MD, PhD — Erasmus Medical Center
• Study coordinator: Mohamed Moussa, MD
• Email: m.moussa@erasmusmc.nl
• Phone: 0685529560

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Assessing the effects of ABBV-324 on liver and lung cancers

  This study is testing a new drug called ABBV-324 to see if it can help adults with advanced liver or lung cancer feel better when taken alone or with another medication.

  Recruiting at 21 sites Phase 1 AbbVie · Duarte, California and 21 other locations · NCT06858813

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• GPC3 targeted CAR-T cell therapy for advanced liver cancer

  This study is testing a new immune therapy using modified T cells to see if it can help people with advanced liver cancer that has a specific marker called GPC3.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05003895

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.